State Street Holds 6.1% Of Arcutis Without Seeking To Influence Control
Arcutis raised its 2026 revenue outlook while commercial spending climbed faster than product sales.
State Street reported a 6.1% passive stake in Arcutis Biotherapeutics, which develops and sells skin-disease treatments, in an SEC ownership filing Tuesday. The holding totaled 7,718,628 common shares as of September 30, 2026, rather than representing a purchase made on the filing date.
A Holding Without A Control Bid
State Street certified that its Arcutis shares were bought and held as part of its regular business, without an aim or effect of influencing the company's control. The passive ownership disclosure describes the holding's purpose, not a campaign to change management.
State Street had shared voting authority over 7,399,852 shares and sole voting authority over none. Its shared authority to dispose of shares covered the full 7,718,628-share holding.
Arcutis had a market capitalization of $3.3 billion as of 6:41 a.m. ET Tuesday.
Sales Grow, Spending Grows Faster
Arcutis reported third-quarter net product revenue of $143.9 million, up 45% from a year earlier, and raised its 2026 net revenue forecast to $535 million–$545 million. Selling and administrative expenses rose faster: up 60% to $99.6 million, which the company attributed largely to more media spending and an expanded sales force.
The commercial push centers on ZORYVE, a steroid-free medicine applied once daily. Its roflumilast-based creams and foam are approved in the United States for plaque psoriasis, atopic dermatitis and seborrheic dermatitis, and the medicine is also sold in Canada. Arcutis markets it to dermatologists and is extending its reach to primary care providers and pediatricians.
Arcutis generated $18.9 million in positive operating cash flow, but said expenses would remain elevated in the fourth quarter and into 2027. The company said the commercial payoff from its primary-care and pediatric sales force and virtual health platform remained uncertain until 2027.
Arcutis Chief Financial Officer Lata Bhairavan said the company would wait until the year closes before providing 2027 guidance.
Sources
- SCHEDULE 13G — STATE STREET CORPORATION re: ARCUTIS BIOTHERAPEUTICS INC (ARQT) — SEC EDGAR
- Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to ... — Yahoo Finance
- Arcutis Biotherapeutics Reports Inducement Grants Under — globenewswire.com